Table 2.
Adjusted Odds of Breast Cancer Multigene Testing (Computerized Data Onlya) Kaiser Permanente Northern California, January 2013 – June 2015
| Predictor | Odds Ratio (95% Confidence Interval) |
|---|---|
| Age at diagnosis | |
| <40 | 12.07 (6.95,20.99)* |
| 40–<50 | 14.58 (10.46,20.32)* |
| 50–<60 | 12.05 (9.03,16.09)* |
| 60–<70 | 5.99 (4.60,7.80)* |
| 70+ | REF |
| Race/Ethnicity | |
| Asian | 0.95 (0.74,1.21) |
| Black | 0.60 (0.41,0.88)* |
| Other or unknown | 2.04 (0.79,5.28) |
| White, Hispanic | 0.96 (0.71,1.32) |
| White, non-Hispanic | REF |
| Tumor size | |
| >0.5 cm to <=1.0 cm | 0.29 (0.22,0.37)* |
| >1.0 cm to <=2.0 | 1.13 (0.91,1.40) |
| >2.0 cm | REF |
| Charlson comorbidity score | 0.89 (0.81,0.98)* |
| Community-level median family incomeb | 1.05 (1.02,1.07)* |
| Oncologist gender | |
| Female | 1.60 (1.21,2.12)* |
| Male | REF |
| Practice group oncology chief: proportion of patients testedc | 1.20 (1.12,1.29)* |
| Percent of variance unexplained by fixed effects that is explained by this level effect | |
| Oncologist level | 7.93% |
| Practice group level | 0.25% |
a
Results from a generalized linear mixed model with data from 2,974 patients, 113 oncologists, and 15 practice groups.
b
Community-level is from census block group characteristics.
c
Odds ratios represent increased odds for each absolute 10% increase in the percent of patients the oncology chief tested.
*
Significant at p<=0.05